tiprankstipranks
Intellia Therapeutics (NTLA)
NASDAQ:NTLA

Intellia Therapeutics Stock Price & Analysis

1,802 Followers

NTLA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$37.08 - $150.53
Previous Close$53.92
Volume1.65M
Average Volume (3M)1.25M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$407.95M
Total Debt (Recent Filing)$21.70M
P/E Ratio-10.1
Beta2.45
Next EarningsNov 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-5.36
Shares Outstanding76,011,784
R-Squared0.17
Standard Deviation0.25
10 Day Avg. Volume1,743,744
30 Day Avg. Volume1,245,300
P/B Ratio4.93
P/S Ratio90.40
P/CF Ratio17.80
P/FCF Ratio-12.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside101.48% Upside
Rating ConsensusModerate Buy
Alpha0.02
Number of Analyst Covering16


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

NTLA FAQ

What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $37.08 and its highest was $150.53 in the past 12 months.
    What is Intellia Therapeutics’s market cap?
    Currently, no data Available
    When is Intellia Therapeutics’s upcoming earnings report date?
    Intellia Therapeutics’s upcoming earnings report date is Nov 03, 2022 which is in 38 days.
      How were Intellia Therapeutics’s earnings last quarter?
      Intellia Therapeutics released its earnings results on Aug 04, 2022. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$1.304 by -$0.026.
        Is Intellia Therapeutics overvalued?
        According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Intellia Therapeutics pay dividends?
          Intellia Therapeutics does not currently pay dividends.
          What is Intellia Therapeutics’s EPS estimate?
          Intellia Therapeutics’s EPS estimate is -$1.29.
            How many shares outstanding does Intellia Therapeutics have?
            Intellia Therapeutics has 76,011,790 shares outstanding.
              What happened to Intellia Therapeutics’s price movement after its last earnings report?
              Intellia Therapeutics reported an EPS of -$1.33 in its last earnings report, missing expectations of -$1.304. Following the earnings report the stock price went down -8.745%.
                Which hedge fund is a major shareholder of Intellia Therapeutics?
                Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 492M.

                  ---

                  Intellia Therapeutics Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  7
                  The Intellia Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Intellia Therapeutics

                  Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis